5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy

被引：97

作者：

Nicholson, SL

Brotchie, JM

机构：

[1] Motac Neurosci Ltd, Manchester M15 6SE, Lancs, England

[2] Univ Manchester, Sch Biol Sci, Manchester, Lancs, England

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2002年 / 9卷

关键词：

levodopa; levodopa-induced dyskinesia; Parkinson's disease; serotonin;

D O I：

10.1046/j.1468-1331.9.s3.1.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

While Parkinson's disease is undoubtedly a disorder with a primary pathology of dopamine neuronal loss, that loss of dopamine and subsequent dopamine replacement therapy leads to imbalances in many non-dopaminergic transmitter systems, including 5-hydroxytryptamine (5-HT). Recent advances in understanding the role of 5-HT in parkinsonism and the generation of side-effects of dopamine replacement therapy (e.g. wearing-off and levodopa-induced dyskinesia) have identified 5-HT1A, 5-Ht(1B) and 5-HT2C receptors as potential therapeutic targets in Parkinson's disease.

引用

页码：1 / 6

页数：6

共 51 条

[1] Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity:: Role of 5-HT1B/1D and 5-HT2 receptors [J].